Who May Be at Risk for Gastroparesis While Taking Ozempic?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Pharmacovigilance

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether the medication could be contributing to gastroparesis—a condition where stomach emptying is delayed. Decades of pharmacovigilance have established that medications can sometimes trigger gastrointestinal motility disorders, and recent case reports have begun to document this association with GLP-1 receptor agonists. This page reviews the published medical literature on Ozempic and gastroparesis, highlighting patient profiles and the typical timeline of symptom onset.

Understanding Gastroparesis and Ozempic's Mechanism

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, with confirmation of retained food in the stomach after a fast. The condition can be idiopathic or secondary to diabetes, surgery, or medication use. In the context of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and weight management, concerns have emerged about its potential to cause or exacerbate gastroparesis. Ozempic works by mimicking the incretin hormone GLP-1, which slows gastric emptying, increases insulin secretion, and reduces glucagon release. This pharmacological effect is central to its therapeutic benefit but also underlies gastrointestinal adverse reactions. The prescribing information for Ozempic documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo in placebo-controlled trials (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Evidence Linking Ozempic to Gastroparesis Symptoms

While the label does not explicitly list gastroparesis as a separate adverse reaction, it includes gastrointestinal adverse reactions with a frequency of less than 5% that are consistent with gastroparesis symptoms: dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the mechanism of delayed gastric emptying induced by GLP-1 receptor agonists provides a plausible pathway linking Ozempic to gastroparesis. Mechanistically, GLP-1 agonists slow gastric motility by inhibiting vagal nerve activity and reducing antral contractions, which can lead to functional gastric outlet delay. This effect is dose-dependent and more pronounced during initial treatment or dose escalation. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The current label does not contain a specific warning for gastroparesis, but it does caution about serious hypersensitivity reactions, including anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a dedicated gastroparesis warning may leave patients and clinicians unaware of the potential for this serious adverse effect, especially in individuals with pre-existing gastric motility disorders or diabetes-related autonomic neuropathy.

Causation and Risk Assessment for Patients

For affected patients, causation considerations include the temporal relationship between Ozempic initiation and symptom onset, the dose-response gradient, and the exclusion of other causes. The timeline between exposure and documented harm is often within weeks to months of starting therapy, particularly during dose escalation, as gastrointestinal adverse reactions are most common during this period. For patients who develop gastroparesis symptoms while on Ozempic, the risk narrative must weigh the benefits of glycemic control against the potential for debilitating gastrointestinal side effects. Discontinuation of Ozempic may lead to symptom resolution, but recovery can be prolonged in some cases. Clinicians should monitor for signs of gastroparesis, such as persistent nausea, vomiting, and early satiety, and consider alternative therapies if symptoms are severe. The evidence suggests that while Ozempic does not cause gastroparesis in all users, its pharmacological effect on gastric emptying can unmask or worsen the condition in susceptible individuals. The lack of a specific warning in the label may contribute to underrecognition and delayed diagnosis, highlighting the need for enhanced patient education and clinical vigilance.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Ozempic cause gastroparesis?

Yes, there is evidence that Ozempic can cause or exacerbate gastroparesis. Ozempic works by slowing gastric emptying, which is its therapeutic mechanism, but this can lead to symptoms consistent with gastroparesis such as nausea, vomiting, and early satiety. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the symptoms of gastroparesis caused by Ozempic?

Symptoms include persistent nausea, vomiting, early satiety, bloating, abdominal pain, dyspepsia, and gastroesophageal reflux. These symptoms overlap with common side effects of Ozempic, and the label lists dyspepsia, eructation, flatulence, and gastritis as occurring in less than 5% of patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

How long after starting Ozempic can gastroparesis develop?

Gastroparesis symptoms typically develop within weeks to months of starting Ozempic, especially during dose escalation. Gastrointestinal adverse reactions are most common during this period, and the label notes that the majority of nausea, vomiting, and diarrhea occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.